An update on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
29 Sep 2017
This is an MRI of child’s liver with severe NAFLD – 38 percent is fat whereas 1 percent is normal. Photo courtesy of UC San Diego School of Medicine.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Related MIMS Drugs